Correlation between serum endocan levels and post-stroke cognitive impairment in elderly patients with acute ischemic stroke
10.3760/cma.j.issn.1673-4165.2025.07.004
- VernacularTitle:血清endocan与老年急性缺血性卒中患者卒中后认知损害的相关性
- Author:
Yuanyuan LIU
1
;
Jing ZHANG
Author Information
1. 西安高新医院神经内科，西安 710082
- Keywords:
Ischemic stroke;
Cognition disorder;
Neoplasm proteins;
Proteoglycans;
Risk factors;
Biomarkers;
Endocan
- From:
International Journal of Cerebrovascular Diseases
2025;33(7):523-527
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the correlation between serum endocan (also known as endocellular-specific molecule-1) levels and post-stroke cognitive impairment (PSCI) in elderly patients with acute ischemic stroke (AIS).Methods:Consecutive elderly patients with AIS admitted to Xi'an Gaoxin Hospital from June 2022 to April 2024 were enrolled prospectively. According to the Montreal Cognitive Assessment score at 6 months after stroke onset, patients were divided into PSCI group (≤22) and non-PSCI group (>22). The demographic data, baseline clinical data and serum endocan levels were collected. Multivariate logistic regression analysis was used to determine the independent related factors of PSCI in elderly patients with AIS. Results:A total of 270 elderly patients with AIS were included, among whom 155 were male (57.4%), aged 73.26±5.63 years. The baseline National Institutes of Health Stroke Scale (NIHSS) score was 10.41±3.77; 122 patients (45.2%) had PSCI. Multivariate logistic regression analysis showed that after adjusting for hypertension, diabetes and smoking, age (odds ratio [ OR] 1.080, 95% confidence interval [ CI] 1.016-1.148; P=0.014], serum endocan >5.59 mg/L ( OR 4.385, 95% CI 1.425-13.494; P=0.010), small vessel occlusive stroke ( vs. cardiogenic embolic stroke: OR 6.296, 95% CI 2.406-16.471; P<0.001), baseline NIHSS score ( OR 1.382, 95% CI 1.238-1.543; P<0.001), anterior circulation stroke ( OR 5.299, 95% CI 1.879-14.945; P=0.002) and left infarction ( OR 2.609, 95% CI 1.340-5.080; P=0.005) were significantly and independently associated with PSCI in elderly patients with AIS. Conclusion:In elderly patients with AIS, higher serum endocan levels may be associated with PSCI, and can serve as a potential serum biomarker for assessing PSCI risk.
